Next Article in Journal
Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1
Previous Article in Journal
Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 13
Issue 1
10.3747/co.v13i1.91
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead

by
A.A. Joy
and
J.R. Mackey
*
Department of Medical Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2006, 13(1), 8-13; https://doi.org/10.3747/co.v13i1.91
Submission received: 1 November 2005 / Revised: 2 December 2005 / Accepted: 3 January 2006 / Published: 1 February 2006

Abstract

The major breast cancer story of 2005 was trastuzumab, a monoclonal antibody directed against the Her-2 oncoprotein, and how it greatly improves outcomes for women with HER2-positive early-stage breast cancer. With early results showing that use of the drug can prevent roughly one half of relapses, adjuvant trastuzumab has been approved, funded, and accepted as the standard of care in many Canadian jurisdictions. In the present brief report, we summarize the four major adjuvant trials, outline some key controversies, and suggest steps to provide more-effective and better-tolerated adjuvant systemic therapy for the relevant patient subgroup.
Keywords: early-stage breast cancer; trastuzumab; adjuvant therapy; docetaxel; paclitaxel; carboplatin; doxorubicin early-stage breast cancer; trastuzumab; adjuvant therapy; docetaxel; paclitaxel; carboplatin; doxorubicin

Share and Cite

MDPI and ACS Style

Joy, A.A.; Mackey, J.R. Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead. Curr. Oncol. 2006, 13, 8-13. https://doi.org/10.3747/co.v13i1.91

AMA Style

Joy AA, Mackey JR. Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead. Current Oncology. 2006; 13(1):8-13. https://doi.org/10.3747/co.v13i1.91

Chicago/Turabian Style

Joy, A.A., and J.R. Mackey. 2006. "Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead" Current Oncology 13, no. 1: 8-13. https://doi.org/10.3747/co.v13i1.91

APA Style

Joy, A. A., & Mackey, J. R. (2006). Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead. Current Oncology, 13(1), 8-13. https://doi.org/10.3747/co.v13i1.91

Article Metrics

Back to TopTop